All News
EULAR 2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
Babies! Safety and Outcomes Data on Pregnancies
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years.
Read Article
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015) prese
Read Article
SLE trials update
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases, with many theoretically well-founded agents appearing to have failed in clinical trials as a result of inefficacy, problem with trial design and/or safety issues.
Read Article
Izokibep Phase 2 in active PsA at Wk 16 results (80mg dose):
⭐️ACR50 52%
⭐️PASI 90 50%
⭐️Resolution of enthesitis LEI 88%
⭐️Safety profile similar to what observed in PsO.
Promising for the enthesitis domain!
@RheumNow OP0258 #EULAR2022 https://t.co/Wm3MvVQzoP
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Singh @NamrataRheum et al. VA study of lymphoma risk with b/tsDMARDs. No increased risk found. HR adjusted time-fixed and time-varying covariates vs csDMARD 1.04 (0.80-1.35) @RheumNow #EULAR2022 POS1434 https://t.co/B6ENz805yl
Richard Conway RichardPAConway ( View Tweet)
#OP0251 #EULAR2022 Any data to support association of RA-ILD with poor #COVID outcomes? A study is US >500 pts (9% ILD) showed ILD as well as poor RA status (RF+ & erosion) increased risk. Detailed analysis inc Radiographic + PFT cd help stratify risk further @RheumNow https://t.co/E89dd38GQS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2022 OP0276: What do patients want for preventative interventions for RA?
⭐️Survey of 1st degree relatives of RA pts (at risk) vs general pop were similar
⭐️'Hypothetical' treatment profile best aligned to abatacept
@Rheumnow https://t.co/r4y7SZbjTA
Eric Dein ericdeinmd ( View Tweet)
Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE in MACE ROR=0.87 [95%CI 0.80-0.95]. INCREASE in DVT: ROR=3.99 [3.15-5.04], PE: ROR=3.47 [2.90-4.13] @RheumNow #EULAR2022 OP0268 https://t.co/lUin7ciXWt https://t.co/Gr4Kvd8F7R
Links:
Richard Conway RichardPAConway ( View Tweet)
Survival of RA-ILD pts w/ lung 🫁 transplantation
Retrospective single centre study
*Mortality 36%
*Usual Interstitial Pneumonia worst prognosis w/ HR 7.13 (did not reach significance, small cohort)
*Survival time comparable to other lung Tx cohorts
#EULAR2022 OP0275 @RheumNow https://t.co/LslPxyXJCp
Aurelie Najm AurelieRheumo ( View Tweet)
OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis targets (proteinuria < 0.7 mg/mg and pred < 7.5 mg/d) at 1 year @AuriniaPharma #EULAR2022 @rheumnow https://t.co/0GoCgP98F2
TheDaoIndex KDAO2011 ( View Tweet)
MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it?
Vigibase: MACE (really MI) & VTE signals there before the scare
Always chance regulatory warnings cause stimulated reporting
but signal here was clear before RCT-driven alerts
OP0268 #EULAR2022 @RheumNow https://t.co/hTJD1gMgyy
David Liew drdavidliew ( View Tweet)
Video: Further Considerations of the ORAL Surveillance Study
Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022
https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT
Links:
Dr. John Cush RheumNow ( View Tweet)
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
Dr. Antoni Chan synovialjoints ( View Tweet)
WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force. #EULAR2022
https://t.co/AiCNQPm6KB https://t.co/kn4rmcbZrH
Links:
Dr. John Cush RheumNow ( View Tweet)
What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formation found in axSpA. #EULAR2022 POS0149 argues for a standardization of this nomenclature. @RheumNow https://t.co/ifrowQnRcn
Dr. Rachel Tate uptoTate ( View Tweet)
To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog
@RheumNow https://t.co/0cTep6MHLu
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
The expanding spectrum of Systemic Autoinflammatory Disease (SAID) by Marco Gattorno using a combination of clinical assessment, genetic testing and imaging to define the phenotype of SAID #EULAR2022 @RheumNow https://t.co/TGYmfExHxD
Dr. Antoni Chan synovialjoints ( View Tweet)
Treat-to-target in RA is held with an almost religious fervour in rheumatology, but it's really hard to follow religiously. What happens if you're only T2T observant on the high holidays?
Answer: the world's not too bad!
(2y is bit short I realise)
POS0111 #EULAR2022 @RheumNow https://t.co/Boh74JmsP3
David Liew drdavidliew ( View Tweet)
Watch: Treatment of Pre-RA: Is Early Already Too Late?
Dr. Aurelie Najm reviews abstract OP0070 presented at the #EULAR2022 meeting. #MedEd
https://t.co/ep4lgtZYcT https://t.co/LTx1RMGdkv
Links:
Dr. John Cush RheumNow ( View Tweet)